Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

103.85 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,986
Open 103.85
Bid (Size) 104.85 (10)
Ask (Size) 104.90 (12)
Prev. Close 103.85
Today's Range 103.85 - 103.85
52wk Range 92.35 - 120.92
Shares Outstanding N/A
Dividend Yield 3.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exploring NYSE:NVS's dividend characteristics.
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, and a promising innovation pipeline. 
Via Benzinga

Performance

YTD
+2.82%
+2.82%
1 Month
-9.16%
-9.16%
3 Month
-11.81%
-11.81%
6 Month
+2.71%
+2.71%
1 Year
+6.96%
+6.96%

More News

Read More
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Via Benzinga
Is NYSE:NVS suited for dividend investing?
Via Chartmill
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Novartis Reports Q3 Momentum, But Shares Lose Support
Via Investor's Business Daily
Looking Into Novartis's Recent Short Interest
Via Benzinga
Why NYSE:NVS is a Top Pick for Dividend Investors.
Via Chartmill
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Via Benzinga
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook
Via Benzinga
Topics Earnings
Exposures Financial
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
Via Investor's Business Daily
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
Via Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
Via The Motley Fool
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Via Benzinga
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
Via Benzinga
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Via The Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
Via Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm
Via Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.